Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation

IART·NASDAQ

$16.10

+2.7%
HealthcareMedical - Devices

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

At a Glance

Live Snapshot
Market Cap$1.25B
EPS-6.7300
P/E Ratio-2.39
Earnings Date07/30/2026
1.91%
Return on Invested Capital
558%
3Y-66.0%
5Y-58.0%
10Y-66.0%
-49.50%
Return on Equity
10914%
3Y-595.0%
5Y-660.0%
10Y-657.0%
-14.34%
Return on Assets
8236%
3Y-409.0%
5Y-487.0%
10Y-448.0%
Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation Management Team

IART · NASDAQ
MS

Mr. Stephen Leonard

Corporate Vice President of Global Operations & Supply Chain

Born 1962(Age 64)
male
ML

Ms. Lea Daniels Knight

Executive Vice President & Chief Financial Officer

Compensation

$1,132,688

Born 1973(Age 53)
female
MM

Mr. Michael J. McBreen

Executive Vice President & President of Codman Specialty Surgical

Compensation

$1,089,907

Born 1966(Age 60)
male
MH

Mr. Harvinder Singh

Executive Vice President & President of International Business

Compensation

$989,719

Born 1967(Age 59)
male
MR

Mr. Robert T. Davis Jr.

Executive Vice President & President of Tissue Technologies

Compensation

$823,714

Born 1959(Age 67)
male
DS

Dr. Stuart M. Essig Ph.D.

Non- Executive Chairman

Compensation

$115,000

Born 1962(Age 64)
MM

Ms. Mojdeh Poul

President, Chief Executive Officer & Director

Born 1963(Age 63)
female
CW

Christopher Ward

Senior Director of Investor Relations

MJ

Mr. Jeffrey A. Mosebrook

Senior Vice President of Finance & Principal Accounting Officer

Compensation

$493,138

Born 1976(Age 50)
male
LI

Laurene Isip

Vice President of Global Corporate Communications & Public Relations

iart

Integra LifeSciences Holdings Corporation Insider Positioning

IART · NASDAQ

During the last 12 months, insiders have purchased $102K worth of IART shares, with no selling activity reported.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

9.0K

102.15K

Sold

0

0.00

Net Activity

+102K

+$102K

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

1
GJA

Graves Jeffrey A

Director

9.0K shares1 transactions

$102K

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $102K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

∞:1

Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.

Insider Participation

High Buying

1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.

SEC Filings

IART - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

April 06, 2026
December 31, 2025
2025
DEF 14A

DEF 14A 2024

N/A

April 04, 2025
December 31, 2024
2024
DEF 14A

DEF 14A 2023

N/A

April 04, 2024
December 31, 2023
2023
DEF 14A

DEF 14A

N/A

April 06, 2023
April 06, 2023
 
DEF 14A

DEF 14A 2022

N/A

April 08, 2022
May 13, 2022
2022
DEF 14A

DEF 14A 2021

N/A

April 09, 2021
May 14, 2021
2021
DEF 14A

DEF 14A 2020

N/A

April 08, 2020
May 13, 2020
2020
DEF 14A

DEF 14A 2019

N/A

April 16, 2019
May 16, 2019
2019
DEF 14A

DEF 14A 2018

N/A

April 06, 2018
May 17, 2018
2018
DEF 14A

DEF 14A 2017

N/A

April 17, 2017
May 23, 2017
2017
Showing 1 to 10 of 31 filings